Azithromycin in the treatment of COVID-19: a review. Issue 2 (1st February 2021)
- Record Type:
- Journal Article
- Title:
- Azithromycin in the treatment of COVID-19: a review. Issue 2 (1st February 2021)
- Main Title:
- Azithromycin in the treatment of COVID-19: a review
- Authors:
- Echeverría-Esnal, Daniel
Martin-Ontiyuelo, Clara
Navarrete-Rouco, María Eugenia
De-Antonio Cuscó, Marta
Ferrández, Olivia
Horcajada, Juan Pablo
Grau, Santiago - Abstract:
- ABSTRACT: Introduction: SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents have been proposed as potential treatments. Azithromycin exhibits both properties and therefore may play a role. Areas covered: This article reviews the pharmacology, pharmacokinetics, clinical efficacy, and safety of azithromycin in viral infections, with emphasis on COVID-19. A literature search of PUBMED was conducted on May 30 th and updated on July 28 th . Expert opinion: Azithromycin presents in vitro activity against SARS-CoV-2 and could act in different points of the viral cycle. Its immunomodulatory properties include the ability to downregulate cytokine production, maintain epithelial cell integrity or prevent lung fibrosis. Azithromycin use was associated with a reduction in mortality and ventilation days in other viral infections. These properties could be beneficial throughout the COVID-19. However, the evidence of its use is scarce and of low quality. Azithromycin has been assessed in retrospective observational studies mainly in combination with hydroxychloroquine, which has shown to provide no benefit. This macrolide presents a well-known safety profile. Upcoming clinical trials will determine the role of azithromycin in the COVID-19 (including the stage of the disease where it offers the greatest benefits and the effect of its combination with other drugs).
- Is Part Of:
- Expert review of anti-infective therapy. Volume 19:Issue 2(2021)
- Journal:
- Expert review of anti-infective therapy
- Issue:
- Volume 19:Issue 2(2021)
- Issue Display:
- Volume 19, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 19
- Issue:
- 2
- Issue Sort Value:
- 2021-0019-0002-0000
- Page Start:
- 147
- Page End:
- 163
- Publication Date:
- 2021-02-01
- Subjects:
- Azithromycin -- antivirals -- immunomodulation -- COVID-19 -- cytokine release syndrome -- pneumonia -- SARS-CoV-2
Anti-infective agents -- Research -- Periodicals
616.90461 - Journal URLs:
- http://informahealthcare.com ↗
http://www.future-drugs.com/publication.asp?publicationid=7 ↗
http://www.tandfonline.com/toc/ierz20/current ↗ - DOI:
- 10.1080/14787210.2020.1813024 ↗
- Languages:
- English
- ISSNs:
- 1478-7210
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002981
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 22640.xml